Smith v. Boehringer Ingelheim Pharmaceuticals, Inc.
886 F. Supp. 2d 911
S.D. Ill.2012Background
- Diversity action involving Pradaxa products liability against Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) with 12(b)(6) motion to dismiss denied.
- Plaintiff Eva Smith alleges Pradaxa caused severe bleeding requiring hospitalization; FDA-approved Pradaxa labeling allegedly lacked adequate warnings and reversal guidance.
- Case sits within Pradaxa MDL context; JPML MDL motion pending for centralized handling; district court notes MDL status does not stay its pretrial proceedings.
- Court considers original and later Pradaxa labeling, and accepts complaint allegations as true for purposes of dismissal.
- Court applies Rule 12(b)(6) standard post-Twombly/Iqbal to determine whether claims are plausible and not merely speculative.
- Learned intermediary doctrine and Restatement (Second) of Torts § 402A Comment K are central to evaluating warnings and design defect claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether the complaint survives Rule 12(b)(6) pleading standards | Smith argues claims are pleaded with enough detail to show plausibility | BIPI contends claims fail under Twombly/Iqbal and heightened pleading requirements | Yes; claims survive and may proceed |
| Whether Pradaxa's design defect or failure-to-warn claims are plausibly pled | Smith alleges unreasonably dangerous design and inadequate warnings | BIPI argues warnings existed and risks were disclosed | Plaintiff's design defect and failure-to-warn claims are plausible |
| Whether Comment K immunity applies to Pradaxa | Pradaxa not shown to be unavoidably unsafe with adequate warnings | Comment K immunizes unavoidably unsafe products | Comment K immunity not available at this stage |
| Whether learned intermediary doctrine bars consumer warnings and affects negligence | Plaintiff alleges inadequate warnings; doctrine does not shield manufacturer | Warning to physicians suffices; consumer warnings not required | Learned intermediary does not bar duty to design reasonably safe product; negligence claim survives |
| Whether fraud-based claims are preempted by FDCA Buckman ruling | Claims address misrepresentations to physicians and public, not FDA fraud | Claims preempted as fraud-on-the-FDA under Buckman | Fraud-based claims not precluded at this stage |
Key Cases Cited
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (U.S. 2007) (plausibility standard for Rule 12(b)(6) cases)
- Ashcroft v. Iqbal, 556 U.S. 662 (U.S. 2009) (clarified plausibility and required more than mere speculation)
- Pugh v. Tribune Co., 521 F.3d 686 (7th Cir. 2008) (survival requires more than labels and conclusions)
- Swanson v. Citibank, N.A., 614 F.3d 400 (7th Cir. 2010) (plaintiff must plead plausibility, not mere speculation)
- Atkins v. City of Chicago, 631 F.3d 823 (7th Cir. 2011) (explains plausibility standard post-Iqbal)
- Gen. Elec. Capital Corp. v. Lease Resolution Corp., 128 F.3d 1074 (7th Cir. 1997) (judicial notice and consideration of public records)
- Brownmark Films, LLC v. Comedy Partners, 682 F.3d 687 (7th Cir. 2012) (documents attached to motion may be considered if referenced in complaint)